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Abstract
Background: Neuroblastoma is one of the most challenging malignancies of childhood, being associated with the highest
death rate in paediatric oncology, underlining the need for novel therapeutic approaches. Typically, patients with high risk
disease undergo an initial remission in response to treatment, followed by disease recurrence that has become refractory to
further treatment. Here, we demonstrate the first silica nanoparticle-based targeted delivery of a tumor suppressive, pro-
apoptotic microRNA, miR-34a, to neuroblastoma tumors in a murine orthotopic xenograft model. These tumors express
high levels of the cell surface antigen disialoganglioside GD2 (GD2), providing a target for tumor-specific delivery.
Principal Findings: Nanoparticles encapsulating miR-34a and conjugated to a GD2 antibody facilitated tumor-specific
delivery following systemic administration into tumor bearing mice, resulted in significantly decreased tumor growth,
increased apoptosis and a reduction in vascularisation. We further demonstrate a novel, multi-step molecular mechanism by
which miR-34a leads to increased levels of the tissue inhibitor metallopeptidase 2 precursor (TIMP2) protein, accounting for
the highly reduced vascularisation noted in miR-34a-treated tumors.
Significance: These novel findings highlight the potential of anti-GD2-nanoparticle-mediated targeted delivery of miR-34a
for both the treatment of GD2-expressing tumors, and as a basic discovery tool for elucidating biological effects of novel
miRNAs on tumor growth.
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Introduction
Neuroblastoma is a childhood cancer derived from precursor
cells of the sympathetic nervous system, occurring primarily in
children under the age of 5 years. Although neuroblastoma is
associated with a high death rate in pediatric oncology, the disease
is highly heterogeneous with respect to clinical behaviour, ranging
from spontaneous regression to rapid progression [1]. Low risk
neuroblastoma patients have a cure rate of greater than 90%,
while high risk patients who are diagnosed over the age of 1 year
have a poor prognosis, with approximately 40% survival rates.
Tumors with amplification of the MYCN transcription factor or
loss of heterozygosity for a large segment of chromosome 11 q
represent two distinct genetic subtypes of the disease with
particularly aggressive clinical phenotypes and poor patient
survival. Patients with high risk neuroblastoma treated with
intensive multi-modal chemotherapy often show an initial
remission, however, disease recurrence that is refractory to further
treatment is common.
GD2 is a glycolipid highly expressed on the cell surface of
neuroblastoma and several other cancers [2], providing a potential
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expression in neuroblastoma tumour samples is substantial [7] and
uniform [8] and recent immunotherapy studies with a human/
mouse chimeric disialoganglioside GD2 (GD2) antibody (ch14.18)
combined with cytokine administration resulted in a significant
improvement in neuroblastoma patient outcome [9] suggesting
that the development of therapeutics directed to GD2 is a
promising concept [10–12]. Although anti-GD2 immunotherapy
was significantly superior to standard therapy for event-free
survival (EFS) (6665% vs. 4665%) and overall survival (OS)
(8664% vs. 7565%) at two years post-treatment [9], longer term
survival rates have not yet been published. Anti-GD2 therapy was
found to result in substantial pain and additional deleterious side-
effects, potentially due to GD2 expression in peripheral neural
tissue [9].
MicroRNAs (miRNAs) are small RNAs that regulate gene
expression at a post-transcriptional level [13,14]. Expression
profiling studies of neuroblastoma primary tumors have
identified many miRNAs whose expression levels have been
significantly associated with poor patient survival [15–22], and
functional studies have demonstrated that several miRNAs are
capable of inducing apoptosis or differentiation when ectopically
over-expressed in neuroblastoma cell lines [23–29]. The
inhibition of endogenous oncogenic miRNAs by antagomirs;
or replacement of tumor suppressive miRNAs, would represent
a novel method of treating neuroblastoma. Although miRNA-
mediated cancer therapeutics have been the subject of intensive
research [21,22,30], the successful application of miRNAs as a
cancer therapy in vivo is very limited [31–35].
A miRNA that targets multiple genetic pathways involved
with cancer cell proliferation, apoptosis or differentiation would
be most desirable for use as a potential therapeutic, as mutation
of multiple target sites would be required for cancer cells to
become resistant. The multi-gene targeting nature of miR-34a is
well documented, with target transcripts including MYCN, BCL2,
SIRT1, NOTCH1, JAG1, CCND1, CDK6 and E2F3 [23,24,28,36–
41]. MiR-34a induces activation of a caspase-mediated apo-
ptotic pathway when over-expressed in neuroblastoma cell lines,
making it ideally suited for miRNA-mediated therapeutics [23].
However, miRNA replacement therapy would require a method
for stable and targeted delivery to tumors.
Here, we demonstrate for the first time the targeted delivery
of miR-34a to neuroblastoma tumors using a disialoganglioside
GD2 (GD2)-antibody conjugated to the surface of porous silica
nanoparticles systemically administered to a well characterized
murine orthotopic xenograft disease model [42]. Although use
of GD2-Ab ch14.18 as a targeting antibody for liposome-
mediated therapeutic delivery has previously been evaluated
[43,44], the main disadvantages of standard liposome formula-
tions include lower drug-loading capacity and rapid drug
leakage compared to the use of nanoparticles of identical size
[45]. In this study, we evaluated silica-based nanoparticles [46]
which are considered a more stable and inert delivery vehicle
with biodegradable and non-toxic properties both in vitro and in
vivo [47–49]. Analysis of tumors treated with miR-34a by
immuohistochemical staining indicated that multiple mecha-
nisms, including increased apoptosis, and surprisingly, decreased
angiogenesis, were responsible for the anti-tumorigenic effects of
this miRNA. In addition, we identify a novel multi-step
molecular mechanism for the anti-angiogenic impact of miR-
34a on neuroblastoma tumors.
Results
Specific Uptake of Anti-GD2 Conjugated Nanoparticles
Containing miRNA and the Effect on Cell Growth in vitro
The use of anti-GD2 conjugated silica nanoparticles as a stable
system for targeted delivery of miR-34a was extensively evaluated
in vitro prior to use in a published murine orthotopic xenograft
model of neuroblastoma [42]. As illustrated in Figure S1, the silica
network of the nanoparticles is dissolved by a hydrolysis dependent
process. The in vivo model utilizes two cell lines which were
modified to stably express luciferase, NB1691 (MYCN amplified)
and SK-N-AS (derived from a non-MYCN amplified tumor with
LOH for chromosome 11 q). Both of these cell lines, along with a
negative control cell line, HEK293 (embryonic kidney origin),
were initially assessed by fluorescence activated cell sorting (FACS)
for GD2 surface protein expression. FACS analysis indicated that
GD2 expression was significantly higher in the two neuroblastoma
cell lines relative to HEK293 (Figure 1A–C). In order to determine
if anti-GD2 conjugated nanoparticles would then bind and be
internalised by GD2 expressing cells at greater specificity than
GD2 negative cells, NB1691 and HEK293 were treated with
different concentrations of anti-GD2 conjugated nanoparticles
doped with FITC (Figure 1D). Four hours after treatment, cells
were washed to remove non-internalised nanoparticles, lysed and
FITC fluorescence, as a result of nanoparticle uptake and
intercellular degradation, was measured using a luminometer. A
final concentration of 6.8610
9 particles/ml (40 mg/ml) yielded
uptake and subsequent FITC release that was approximately 7.6
fold higher in NB1691 cells relative to HEK293 (normalised to
non-coated FITC-doped nanoparticles). Notably, higher concen-
trations of GD2-FITC-NPs resulted in some nanoparticle uptake
by HEK293 cells, consistent with the results of FACS analysis
indicating a minimal level of GD2 expression on the cell surface
(Figure 1A).
In order to evaluate if miRNAs which are non-covalently
encapsulated within the silica matrix of the nanoparticle would be
released into the cellular cytoplasm after uptake, we constructed
anti-GD2-conjugated nanoparticles encapsulating either miR-34a
or a scrambled negative oligonucleotide. Treatment of NB1691,
SK-N-AS and HEK293 cells in vitro with 6.8610
9 particles/ml
(40 mg/ml) resulted in a significant up-regulation of miR-34a in
the neuroblastoma cell lines, but not in HEK293 (Figure 1E),
indicating exclusive binding and release of the nanoparticle
contents to GD2 expressing cells. Moreover, the release of miR-
34a in NB1691 and SK-N-AS cells resulted in a significant
increase in caspase 3/7 activation (Figure 1F *p,0.05) and a
decrease in cell viability, as determined by both an acid
phosphatase assay (Figure 1G–H ***p,0.001) and cell counting
(Figure S2). No apoptotic response was detected for HEK293 cells,
due to the specificity of the anti-GD2-NPs for GD2 expressing cells
(Figure 1I). To confirm that HEK293 cells are susceptible to miR-
34a induced apoptosis, miR-34a was transfected into these cells,
resulting in ectopic over-expression (Figure. S3A) and a significant
decline in cell viability (Figure S3B). We also determined that
other cell lines of non-malignant origin, such as IMR-90
fibroblasts are also adversely affected by miR-34a (Figure S4A
and B), further underscoring the importance for the development
of a system for targeted delivery in vivo.
Targeting of Neuroblastoma Tumors by Systemically
Administered Anti-GD2 Conjugated Nanoparticles
FITC-anti-GD2-NPs or FITC-NPs were systemically adminis-
tered to tumor bearing mice at day 14, after tumor establishment
had been verified.
Neuroblastoma Inhibition by miR-34a Nanoparticles
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fold greater than in healthy organs (liver, spleen, kidney, lung and
heart) scanned ex vivo (Figure 2A,B), indicating the specificity of
anti-GD2-NPs. Among the normal organs, FITC signal was
highest in liver, which could potentially be due to the detoxifica-
tion function of this organ. Most importantly, mean fluorescence
intensity of tumors from mice injected with FITC-anti-GD2-NPs
was 13.9 fold higher (Figure 2C;* p,0.05) than tumors from mice
injected with FITC-nanoparticles lacking GD2 antibody, confirm-
ing targeted delivery (Figure 2C).
Anti-tumorigenic Effect of Anti-GD2 Conjugated
Nanoparticles Bearing miR-34a in vivo
Given the success of our in vivo targeting experiments, we then
evaluated anti-GD2-coated nanoparticles encapsulating miR-34a
to assess the impact on neuroblastoma tumors using the NB1691
luc
and SK-N-AS
luc orthotopic xenograft models. Cohorts of
NB1691
luc or SK-N-AS
luc tumor bearing mice were systemically
administered either anti-GD2-miR-34a-NP or anti-GD2-miRneg-
NP (containing a scrambled oligonucleotide) at day 14, 17 and 20
post-tumor establishment. Equivalency of tumor sizes in miR-34a
Figure 1. Specific uptake of anti-GD2-nanoparticles exclusively by GD2 expressing cells. Effects on growth and caspase activity by anti-
GD2 conjugated nanoparticles containing miR-34a. (A) FACS analysis, using an anti-GD2 primary antibody and goat anti-mouse IgG2a-PE secondary
antibody indicated little, if any, GD2 surface antigen on HEK293 cells. Conversely NB1691 (B) and SK-N-AS (C) cells showed significant GD2 reactivity.
(D) Varying concentrations of FITC-anti-GD2-NPs were added to cell culture media of NB1691 or HEK293 (1610
6 cells). A concentration of 6.8610
9
particles/ml (40 mg/ml) was the optimal dosage tested in vitro for specific delivery of encapsulated FITC fluorophore to NB1691 neuroblastoma cells
with minimal incorporation into HEK293 cells. (E) Anti-GD2-miR34a or control-anti-GD2-nanoparticles were added to adhered neuroblastoma SK-N-AS
and NB1691, and to HEK293 cells for 4 hours in standard media. Media was removed, the cells washed and media was replaced. RNA was isolated
from these cells after 24 hours and assessed for miR34a levels. Anti-GD2-miR34a-NPs treatment (40 mg/ml) led to ,2 fold increase in miR-34a levels in
NB1691 cells, ,30 fold increase in SK-N-AS cells (*p,0.05, n=3), with no significant change in miR-34a transcript levels in HEK293 cells. (F) NB1691
and SK-N-AS cells showed a significant increase in caspase 3/7 activity relative to anti-GD2-miRneg-NP-treated cells after 72 hrs (*p,0.05, n=3) while
HEK293 cells showed no significant increase in caspase activity under these conditions. Acid phosphatase assays indicated a significant reduction in
viable cell numbers for (G) NB1691 and (H) SK-N-AS cells treated with anti-GD2-miR34a-NPs, over a 96 hour period (***p,0.001) relative to anti-GD2-
miRneg-NP-treated controls. (I) HEK293 cells showed no significant reduction of viable cells following treatment with anti-GD2-miR34a-NP (p.0.05,
n=3).
doi:10.1371/journal.pone.0038129.g001
Figure 2. Targeting of neuroblastoma by systemically administered anti-GD2 conjugated nanoparticles. (A) Systemic administration
through lateral tail injection of FITC-anti-GD2-NPs (1 mg/ml) resulted in targeted delivery of FITC dye predominantly to tumors (indicated by
fluorescence intensity color map generated from scans using IVIS instrumentation). (B) FITC-anti-GD2-NP-treated organs have significantly less
fluorescence than isolated tumors (*p,0.05, n=425) and (C) FITC-anti-GD2-NP treated tumors showed significantly greater presence of FITC dye
relative to FITC-NP treated tumors (*p,0.05, n=425).
doi:10.1371/journal.pone.0038129.g002
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ultra-sonography and bioluminescence analysis prior to injection
(at day 13 post-tumor induction; Figure S5). Monitoring of tumors
by bioluminescent imaging on days 18, 21 and 25 revealed a
significant reduction in the bioluminescent intensity of NB1691
luc
and SK-N-AS
luc tumors treated with anti-GD2-miR-34a-NPs
relative to negative control (Figure 3A–D). Measurements of
post-mortem tumor volumes and weights (day 25) confirmed the
highly significant reduction in tumor growth in anti-GD2-miR34a-
NP treated mice (Figure S6). Significantly enhanced miR-34a
levels were detected by qPCR in NB1691
luc and SK-N-AS
luc
tumors treated with anti-GD2-miR34a-NP relative to those treated
with anti-GD2-miRneg-NP (Figure 3E and F). Interestingly, two of
the SK-N-AS
luc tumors which grew faster than the median had no
increase in miR-34a levels (Figure 3D and F), indicating that they
had not been successfully or significantly transduced by anti-GD2-
miR34a-NPs.
Evaluation of non-specific delivery of miR-34a to normal organs
was paramount to ensuring specific targeting of the anti-GD2-NPs
to the neuroblastoma tumor. MiR-34a levels in healthy liver,
kidney and lung from each animal treated with either anti-GD2-
miR34a-NP or anti-GD2-miRneg-NP were evaluated by qPCR to
assess potential off-target delivery of the miRNA. None of the
organs exhibited any significant increase in mature miR-34a
transcript levels subsequent to treatment, relative to anti-GD2-
miRneg-NP treated controls (Figure S7). Blood chemistries were
analysed in anti-GD2-miRneg-NP and anti-GD2-miR34a-NP-
treated animals to evaluate the effects, if any, administration of
silica nanoparticles might have on the animal. From the data
analysed (Figure S8), systemic tail vein injection of either miR-
negative control or miR-34a– anti-GD2-nanoparticles did not
appear to cause significant adverse effects on kidney and/or liver
function. It is also noteworthy that mice treated with anti-GD2-
miR34a-NP (three doses of 1.7610
11 NP/ml [1 mg/ml]) ap-
peared active and healthy throughout the course of the treatment
period, devoid of symptoms such as neuropathic pain which has
been associated with anti-GD2 immunotherapy in patients [50].
The equivalent total amount of anti-GD2 attached to the surface
of the nanoparticles injected into mice was ,3.6 fold less than
what is used for immunotherapy in humans, which could explain
why the mice had no detectable side effects associated with pain.
This calculation is based on a total dose in humans of 56.76 mg
antibody/kg body weight, administered in 6 cycles over 14 days.
miR-34a Over-expression Launches a Cascade of
Molecular Events in Tumors
The levels of MYCN, a validated target of miR-34a that is
amplified in some neuroblastoma tumors and cell lines, were
assessed to further understand the molecular mechanisms leading
to a reduction in tumor growth. The results of qPCR analysis
highlighted a significant decrease in MYCN mRNA levels in the
NB1691
luc tumors (MYCN amplified) (Figure 4A). There was not a
statistically significant difference between anti-GD2-miR34a-NP
relative anti-GD2-miRneg-NP. This is not surprising given the
very low level of MYCN expression in SK-N-AS (Figure 4B). The
decrease in MYCN mRNA in NB1691
luc tumors was validated at
protein level by western blot (Figure 4C and D). NME1, which is
transcriptionally activated by MYCN [51], was down-regulated in
the tumors treated with anti-GD2-miR34a-NP relative to anti-
GD2-miRneg-NP, illustrating that miR-34a was also producing
secondary effects in addition to its direct targeting of 39 UTRs
(Figure 4E and F).
Targeted delivery and over-expression of miR-34a resulted in a
significant increase in apoptosis, as demonstrated by TUNEL
staining of paraffin embedded tumor sections of both NB1691
luc
and SK-N-AS
luc tumors (Figure 5A–C). Cell proliferation was also
significantly reduced in the miR-34a treated tumors, as deter-
mined by KI67 immunohistochemical staining (Figure 5D–F).
CD34 immunohistochemical staining, which detects vascular
endothelial cells, indicated that over-expression of miR-34a also
had a very significant negative impact on tumor vascularisation, or
angiogenesis (Figure 5G–I).
Molecular Events Associated with Decreased Tumor
Vascularisation
Although the positive impact of miR-34a on promoting
neuroblastoma cell apoptosis is well documented [23], the
mechanism leading to the observed decrease in angiogenesis is
poorly understood. To further elucidate this mechanism, mRNA
from four NB1691 tumors treated with anti-GD2-miR34a-NP,
along with an equivalent number of negative control tumors, were
analyzed using TaqMan low density arrays representing 95 genes
involved with angiogenesis. Of note, mRNA levels for tissue
inhibitor of metalloproteinases-2 (TIMP2) were significantly up-
regulated in the miR-34a treated tumors relative to the negative
controls (Figure 6A) and this increase was also validated at protein
level (Figure 6B). This finding is highly significant given that
TIMP2 is an important anti-angiogenic factor [52,53].
To explore the possibility that MYCN might be directly binding
to the TIMP2 promoter and directly repressing transcription, we
examined previously published genome-wide MYCN binding site
data for neuroblastoma [54]. There was no enrichment for
MYCN binding at this promoter. We also assessed the possibility
that the up-regulation of TIMP2 might be mediated by a targeting
miRNA that had become down-regulated in the tumors treated
with anti-GD2-miR34a-NP. Intriguingly, several members of the
oncogenic miR-92 polycistronic clusters mapping to chromosomes
13 and X, which are positively regulated by MYCN binding to
their promoter regions [55,56], are computationally predicted to
target the TIMP2 39 UTR (Figure 6C). Overall, members of the
miR-92 clusters mapping to chromosome 13 and X had
significantly lower expression in the miR-34a treated tumors
relative to negative control, presumably due to the substantial
decrease in MYCN levels resulting from miR-34a targeting
(Figure 6D and E). In order to experimentally confirm that
MYCN was repressing TIMP2 through the up-regulation of miR-
92 cluster members, we used the well characterized SHEP-
TET21N cell line containing a repressible MYCN transgene to
determine if TIMP2 levels increased when MYCN levels were
repressed. Treatment of these cells with doxycycline repressed
both MYCN expression (,50 fold; Figure 6F) and the expression
of miR-92 cluster members (5 to 10 fold; Figure 6G), resulting in
an approximate 4 fold increase in TIMP2 mRNA (Figure 6F).
It was also of interest that the expression of several miR-92
cluster members (17, 18a, 19a, 20a, 20b and 106a) was inversely
correlated with TIMP2 expression in a panel of primary
neuroblastoma tumors, and that low expression of TIMP2 in
tumors is associated with poor overall and event free patient
survival (Figure S9). In order to confirm that TIMP2 was a direct
target of miR-92 cluster members, a segment of the TIMP2 39
UTR containing the miR-20b, miR-17-5p, miR-106a and miR-
20a seed site (all the same sequence, Figure 6C) was cloned into a
luciferase reporter plasmid. Co-transfection of this construct with
miR-20b mimics into NB1691 cells significantly reduced luciferase
activity relative to a negative control oligonucleotide (Figure 6H),
while mutation of the seed site abrogated the effect of miR-20b on
luciferase activity, thus we conclude that miR-20b, and potentially
other miR-92 family members directly target TIMP2.
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PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e38129Figure 3. Anti-neuroblastoma effect of anti-GD2 conjugated nanoparticles bearing miR-34a in vivo. Bioluminescent images
representative of mice bearing (A) NB1691
luc tumors treated with anti-GD2-miRneg-NP (left) or anti-GD2-miR34a-NP (right), along with representative
mice bearing (B) SK-N-AS
luc tumors treated with anti-GD2-miRneg-NP (left) or anti-GD2-miR34a-NP (right) were obtained at day 25. Tumor growth
curves from (C) mice bearing NB1691
luc tumors treated with anti-GD2-miRneg-NP (black line) or anti-GD2-miR34a-NP (red line) and (D) mice bearing
SK-N-AS
luc tumors treated with anti-GD2-miRneg-NP (black line) or anti-GD2-miR34a-NP (red line). Time points for systemic administration of
nanoparticles are indicated by the symbol m. Differences in tumor growth between mice injected with anti-GD2-miR34a-NP versus anti-GD2-miRneg-
NP were statistically significant for both models (NB1691
luc n=8, *p,0.05) (SK-N-AS
luc *p,0.05 for n=8 and **p,0.01 for n=6). For the SK-N-AS
luc
model, two tumors grew significantly faster than the median and are represented in the growth curve for all 8 tumors (red line). The purple line
represents the growth curve without these two tumors (n=6). Mature miR-34a transcript levels were significantly higher in anti-GD2-miR34a-NP
treated tumours relative to anti-GD2-miRneg-NP-treated control tumors in both the (E) NB1691
luc (***p,0.001, n=8) and (F) SK-N-AS
luc (*p,0.05,
n=8). Notably, the two SK-N-AS tumors with increased growth from (D) had poor uptake of miR-34a (arrow).
doi:10.1371/journal.pone.0038129.g003
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The targeted delivery of therapeutics to tumors is still a major
challenge in cancer research, holding the potential to mitigate
deleterious side effects, as well as increase the efficacy of treatment
by delivering a higher concentration of drug or nucleic acid to the
site of disease. To date, relatively few strategies have been
developed to target silica nanoparticles to tumor cells using in vivo
models. Patil et al [57] used biotin as a targeting ligand for delivery
of nanoparticles to breast cancer xenograft tumors which over-
express biotin receptors, demonstrating that targeted delivery
permitted a greater accumulation of nanoparticles in the tumors.
The tumor targeting antibody GC4 has also been used to
successfully target silica nanoparticles containing siRNA and
miRNA to melanoma cells in a murine model of melanoma
metastasis [58]. In this study, we demonstrate that the bioconjuga-
tion of GD2 ch14.18 antibody to the surface of porous silica
nanoparticles containing miR-34a results in the targeted delivery
of these functionalized nanoparticles and significant inhibition of
neuroblastoma tumor growth in a murine orthotopic disease
Figure 4. Targeting of MYCN by miR-34a in vivo. (A) MYCN, a validated target of miR-34a, mRNA levels were significantly reduced in GD2-
miR34a-NP treated NB1691
luc tumors relative to negative controls (**p,0.001, n=8) (B) qPCR analysis of SK-N-AS
luc tumors did not indicate a
statistically significant difference between anti-GD2-miR34a-NP and anti-GD2-miRneg-NP treated tumours, potentially because levels of MYCN
expression are very low in this cell line. Three SK-N-AS tumors treated with negative control nanoparticles appeared to have somewhat higher
expression then the median, although this level of expression is very low compared to MYCN amplified tumors (C) MYCN reduction in NB1691
luc was
validated at a protein level by Western Blot and (D) protein suppression was quantified using densitometry. NME1, a validated MYCN target, had
reduced mRNA levels in anti-GD2-miR34a-NP treated NB1691
luc tumors (E) and SK-N-AS
luc tumors (F) relative to negative controls (*p,0.05, n=8), as
evaluated by qPCR.
doi:10.1371/journal.pone.0038129.g004
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delivery vehicle might also be applicable to other tumors of
neuroectodermal origin, such as melanoma, which express high
levels of the surface antigen GD2 [59]. In addition to being a
potential therapeutic, the use of GD2 antibody conjugated
nanoparticles for targeted delivery of miRNAs also represents a
basic discovery tool for elucidating the effects of novel miRNAs on
tumor growth.
The GD2 antibody acts as a docking mechanism to the
corresponding GD2 antigen, leading to receptor-mediated endo-
cytosis via clathrin-coated pits and formation of endosomal
compartments within the cell [60,61]. The precise mechanism of
nanoparticle-cargo release has not fully been elucidated; however,
endosomal acidification might play a role in nanoparticle
degradation and content release. Degradation and dye content
release of synthesized nanoparticles used during this study was
confirmed in situ (Figure S1) proving the degradative properties of
these delivery vehicles. The use of GD2 antibody in the treatment
of cancers leads to antibody dependent cellular cytotoxicity
(ADCC) [10,11], complement dependent cytotoxicity (CDC)
Figure 5. Pro-apoptotic and anti-angiogenic activity of GD2 targeted nanoparticles containing miR-34a. Tumors of mice treated with
anti-GD2-miR-34a-NPs and negative controls were analyzed by TUNEL staining on paraffin embedded section of SK-N-AS
luc (a) and NB1691
luc (b)
tumors. In both tumor subtypes, treatment with anti-GD2-miR34a-NPs led to a significant increase in apoptosis (c, ***p,0.001, n=8).
Immunohistochemistry staining with CD34 showed a marked decrease in the endothelial cell marker subsequent to anti-GD2-miR34a-NP treatment
(d-f, ***p,0.001, n=8). KI67 staining showed reduced proliferation in anti-GD2-miR34a-NP treated cohorts (g-i, ***p,0.001, n=8).
doi:10.1371/journal.pone.0038129.g005
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[64]. It is unlikely that the presence of GD2 antibody conjugated to
the surface of the nanoparticle is contributing an anti-tumorigenic
effect in this study, given that negative control particle also
possessed conjugated GD2 antibody; and tumor progression within
this cohort was extremely aggressive.
As demonstrated in this report, we were able to over-express
miR-34a from 4 to 25 fold in NB1691 tumors, and 2 to 7 fold in
SK-N-AS tumors. The lower incidence of uptake of miR-34a by
SK-N-AS cells might be due to lower expression of GD2 on the
cell surface. In this regard, it is interesting to note that FACs
analysis for GD2 expression indicated a bimodal distribution for
SK-N-AS, with a large population of cells clearly having less GD2
than NB1691 cells. Nevertheless, even a 2 to 7 fold increase in
miR-34a levels negatively impacted SK-N-AS tumor growth.
Based on prior in vitro studies of miR-34a in neuroblastoma cell
lines, we expected that targeted delivery of miR-34a to tumors in
an orthotopic model would induce apoptosis [23–25,28]. Although
a statistically significant increase in apoptosis was detected, the
over-expression of miR-34a in the tumors also had a profound
negative impact on vascularization, as determined by CD34
staining. For several reasons, the inhibition of vascularisation is
likely related to the decrease in MYCN activity caused by direct
miR-34a targeting of its 39 UTR. As demonstrated in this report,
the decline in MYCN corresponded with a decrease in the levels of
miR-92 polycistronic cluster members in NB1691 tumors, which
are positively regulated by this transcription factor. TIMP2 is a
direct target of some of these miRNAs, and therefore their down-
regulation released TIMP2 from repression. TIMP2 inhibits
angiogenesis through matrix metalloproteinases which are re-
quired to degrade the extracellular matrix and also through
suppression of endothelial cell proliferation [52,53]. However, the
decline in MYCN mediated by miR-34a might also inhibit
angiogenesis in other ways from those detailed in this publication.
For example, Kang et al [65] demonstrated that siRNA mediated
inhibition of MYCN leads to blocked secretion of vascular
Figure 6. Molecular events involved with miR-34a anti-angiogenic effects. (A) qPCR and (B) western blot analyses of TIMP2 mRNA (n=4
tumors) and protein levels (n=3 tumors) from NB1691 tumors treated with anti-GD-miR-neg-NP or anti-GD20miR34a-NP. (C) Computationally
predicted target sites on the 39 UTR of TIMP2 for miR-92 polycistronic cluster members from chromosome 13 and X. qPCR analysis of miR-92 cluster
members from chromosome 13 (D) and chromosome X (E) in tumors treated with anti-GD-miR-neg-NP (n=8) or anti-GD20miR34a-NP (n=8). (F) qPCR
analysis of MYCN and TIMP2 expression in SHEP TET21 cells possessing a repressible MYCN transgene. Expression levels of these genes in cells treated
(DOX+) and untreated (DOX-) with doxycycline are displayed. (G) Expression levels of miR-92 cluster members in SHEP TET21 following treatment
with doxycycline (MYCN low expression state)(n=5 biological replicate experiments). (H) Luciferase assays following co-transfection of NB1691 cells
with a reporter construct containing a wild type TIMP2 39 UTR region and either miR-20b mimics or a negative control oligonucleotide (n=2).
Luciferase activity following co-transfection of the same cell line with a plasmid having a mutated binding site for miR-20b and either miR-20b mimics
or a negative control oligonucleotide is also displayed.
doi:10.1371/journal.pone.0038129.g006
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recently, Patterson et al [66] demonstrated that treatment of
neuroblastoma cells with the MDM2 small molecule inhibitor,
Nutlin-3a, significantly reduces angiogenesis, which is also
consistent with our findings given that MYCN is a positive
transcriptional regulator of MDM2. Thus, miR-34a up-regulation
in tumors has an anti-angiogenic effect potentially mediated
through direct inhibition of MYCN.
MiR-34a mediated inhibition of MYCN also holds potential
benefits in the treatment of drug-resistant tumors given that
MYCN has a documented role in the development of drug
resistance. In neuroblastoma, direct regulation of ATP-binding
cassette (ABC) transporters by MYCN implicates MYCN as a
mediator of drug-resistance in neuroblastoma [67]. SiRNA-
mediated MYCN suppression led to a down-regulation of the
multidrug-resistance associated protein (MRP) gene and a
corresponding increased sensitivity to a broad range of drugs
including vincristine, doxorubicin, and sodium arsenate [68].
Moreover, miR-34a has been directly implicated in mediating
chemo-drug resistance or sensitivity in a number of different
cancers [69,70].
Given that miR-34a has pro-apoptotic effects on cell lines of
non-malignant origin, it seems likely that off-target delivery of this
miRNA could have adverse effects on healthy vasculature and
tissues. Targeted delivery could be particularly important in the
context of paediatric malignancies, as off target delivery could
potentially retard normal growth and development in young
children. Although non-targeted lipid based delivery of miR-34a
was shown to have anti-tumorigenic effects on a mouse xenograft
model of prostate cancer, with the miR-34a formulation being
tolerated by mice [33], targeting of miRNAs in humans,
particularly paediatric patients, would be of particular importance
in avoiding or limiting, long term deleterious and developmental
effects such as those which currently occur with chemotherapeutic
regimes as a result of off-target genetic alterations. Further studies
in pre-clinical models to assess the impact, if any, of off-target
delivery of miR-34a, would be of benefit to assess potential health
risks.
Targeted delivery should provide a higher concentration of
miR-34a to the tumor site, potentially increasing the efficacy of
this mode of treatment. Future studies will be focused on
determining optimal treatment doses and schedules, as well as
optimizing encapsulation of chemotherapies in addition to miR-
34a in porous silica nanoparticles for in vivo analysis of
neuroblastoma.
Materials and Methods
Primary Neuroblastoma Tumours
Primary neuroblastoma tumours used in the Affymetrix Array
microarray profiling were a subset of tumors previously described
by Bray et al [15]. Twelve of the tumours were from a Tumor
Bank at Our Lady’s Children’s Hospital, Dublin, and 30 came
from the COG Tumor Bank, Phildelphia, P.A. The biological and
clinical characteristics of the tumors are described in Table S1.
The research was approved by the Ethics Committees of the Royal
College of Surgeons in Ireland and Our Lady’s Children’s
Hospital, Dublin, Ireland.
Cell Lines
NB1691
luc and SK-N-AS
luc were engineered to express the
enzyme firefly luciferase by the laboratory of Dr. Andrew
Davidoff, as previously described [42], and maintained in
RPMI-1640 supplemented with heat-inactivated foetal bovine
serum (10%), l-glutamine (1%) and 100 mg/mL Zeocin (InVivo-
Gen, San Diego, California). HEK293 cells were purchased from
the European Collection of Cell Cultures and grown in DMEM
supplemented with FBS (10%) and l-glutamine (1%). Each cell line
was validated by aCGH profiling for identification of previously
published genomic abnormalities.
Reverse Transcription, Real-time qPCR and Western
Blotting
Total RNA was extracted using a miRNeasy kit (Qiagen Inc,
Valencia, CA). Reverse transcription was carried out using 50 ng
of total RNA and the TaqMan reverse transcription kit (Applied
Biosystems). qPCR was carried out on the 7900 HT Fast Real-
time System (Applied Biosystems). TaqMan qPCR probes and
stem loop primers for miR-34a and miR-92 family members were
obtained from Applied Biosystems. These probes only recognize
mature miRNA sequences. b-actin, was used for normalization. A
relative fold change in expression of target miRNA/gene
transcripts was determined using the comparative cycle threshold
method (2
2DDCT). Total protein was isolated from cells using a T-
PER tissue protein extraction reagent (Thermo Scientific). Anti-
MYCN antibody (n-mycn: Santa Cruz (SC-53993), 1:500) or anti
a-tubulin (Abcam (AB7291), 1:5000 used for loading controls).
Fluorescence Activated Sorting Analysis
Log phase cells (2610
6) were harvested and stained with GD2
primary antibody (Santa Cruz, sc-53831) and a goat anti-mouse
IgG2a-PE secondary antibody (Santa Cruz, sc-3738). Cells were
then analyzed by a FACS Calibur (BD Bioscience).
Synthesis of FITC Dye Doped Silica Nanoparticle; Empty
or Containing Either miR-34a or a miR-negative Control
All chemicals were obtained from Sigma Aldrich, (Sigma-
Aldrich Corp., St. Louis, MO) unless otherwise stated.
Silica nanoparticles (w=74 nm) containing fluorescein (3 (w/
w)) and synthetic premiR-34a (0.1 (w/w)), or a scrambled miR-
negative control (0.1 (w/w)) were prepared using a microemulsion
method [71]. The mechanism for formation of silica nanoparticles,
outlined in Figure S1C, involves hydrolysis and condensation of a
silica precursor (tetraethylorthosilicate). The proposed mechanism
of drug delivery is dissolution of the nanoparticle and release of the
dye under physiological conditions via hydrolysis of the silica
network. This hydrolysis is simply the reverse of the condensation
step which is also described in detail by Park et al. [72].
Conjugation of GD2-Ab ch14.18 to the Nanoparticles
Conjugation was performed according to a previously published
protocol using PAMAM dendrimers [73]. The NP–antibody
bioconjugates were aliquoted (1.7610
11 nanoparticle ; 1 mg) and
later re-suspended in sterile cell culture media immediately prior
to use.
MicroRNA and Nanoparticle Treatment of NBL Cells
in vitro
The Pre-miR
TM to miR-34a (30 mM) and the pre-miR-negative
control miRNA (negative control 1, Applied Biosystems) were
reverse transfected into NB1691, SK-N-AS and HEK293 cell lines
using the transfection agent siPORT
TM NeoFX
TM (Applied
Biosystems/Ambion, Austin, TX). For nanoparticle experiments,
NB1691, SK-N-AS and HEK293 cell lines were seeded 24 hours
prior to treatment and then treated with a final concentration of
6.8610
9 particles/ml (40 mg/ml). Each vial of freeze-dried
nanoparticles (1mg containing 1.7610
11 particles) was resus-
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from the light (stock solution of nanoparticles 1.7610
11 particles/
ml or 1 mg/ml) and appropriate dilutions were made accordingly.
Fluorescence Analysis
Following treatment with FITC doped nanoparticles, cells were
lysed using a RIPA buffer and centrifuged at 14,000 rpm for 15
minutes at 4uC. The relative fluorescent units (RFUs) of isolated
supernatant (50 ml) was then detected using a Viktor Microplate
luminometer (Molecular Devices, Sunnyvale, CA).
Acid Phosphatase Assays
Cells were transfected in 96-well plates (1610
4 per well). At
designated time points post-treatment, cells were washed with PBS
and 10 mM p-nitrophenol phosphate in sodium acetate (0.1 M)
with triton X-100 (0.1%) being added. Plates were incubated at
37uC for two hours in the dark and the reaction was stopped with
sodium hydroxide (50 ml 1 M) per well. Absorbance was measured
at 405 nm.
Caspase 3/7 Activity Assay
NB1691, SK-N-AS and HEK293 cells were plated in quadru-
plicate in 96-well plates. 72 hours after nanoparticle treatment or
miRNA transfection, caspase activity was measured using the 3/7
Caspase detection kit from Promega (Madison, WI) in accordance
with manufacturers protocols. Luminescence was read on a Viktor
Microplate luminometer (Molecular Devices, Sunnyvale, CA).
In vivo Targeting and Nanoparticle Delivery
All animal experiments were carried out using CB-17/SCID
mice (Taconic, Hudson, New York) and were performed in
accordance with a protocol approved by the Institutional Animal
Care and Use Committee of St Jude Children’s Research
Hospital, Memphis, Tennessee. Retroperitoneal tumors were
established by injection of 2610
6 NB1691
luc or SK-N-AS
luc cells
behind the left adrenal gland via a left subcostal incision under
administration of isoflurane (2%), and tumors were allowed to
develop over 13 days (n=8 per cohort). Fluorophore-doped-anti-
GD2-coated NPs, fluorophore-doped-NPs, anti-GD2-miR34a-
NPs, or anti-GD2-miRneg-NPs-treated (10 mg/ml) were admin-
istered via lateral tail vein injection to mice with pre-established
retroperitoneal neuroblastoma (day 21 for the targeting exper-
iments with FITC doped nanoparticles; day 13 for microRNA
encapsulated nanoparticles. Scanning of resected tumours and
organs ex vivo, or of tumors in vivo, was performed using an IVIS
Imaging System 100 Series (Xenogen Corporation, Alameda,
CA). For experiments using nanoparticles with encapsulated
miR-34a or a negative control oligonucleotide, animals in each
cohort were tumor size matched using ultrasound and biolumi-
nescent imaging, and each cohort received repeat injections with
anti-GD2-miRneg-NPs or anti-GD2-miR34a-NPs (10 mg/ml) at
3 day intervals (days 14, 17 and 20 post-tumor induction). Prior
to imaging, mice received an intraperitoneal injection of D-
Luciferin (150-mg/kg, Caliper Life Sciences, Hopkinton, MA).
Tumor Immunohistochemistry
Formalin-fixed, paraffin-embedded, 4-mm thick tumor sections
were stained with rat antimouse CD34 antibody (RAM 34;
PharMingen, San Diego, Calif) or KI67 (VP-K451; Vector
Laboratories, Burlingame, CA). TUNEL staining was carried
out in accordance with previously published protocols [35] and all
images were analysed using an Olympus U-SPT microscope as
previously described [74].
Cloning of 39-UTR of TIMP2 and Luciferase Assays
A 199 bp DNA fragment containing the TIMP2 39UTR was
PCR amplified from genomic DNA using flanking primers (Figure
S10A) and cloned into the pCR4-TOPO vector (Invitrogen,
Grand Island, NY). The DNA fragment of the TIMP2 39UTR was
then sub-cloned into psiCHECK2 vector (Promega) to generate
psi-TIMP2-39UTR. The resultant clone was sequence verified and
used to create the deletion mutant for miR-20b binding sites using
the GeneTailor mutagenesis system (Invitrogen). Luciferase assays
were performed as previously reported [27]. The sequence of both
wild type and mutant 39 UTR for TIMP2 is presented in Figure
S10B.
Statistical Analysis
The Mann-Whitney non-parametric, one-tailed unpaired test
was used to analyze significance of all data. (data is plotted as the
median + standard error of the mean).
Supporting Information
Figure S1 Evaluation of dye leaching from synthesized
silica nanoparticles.
(PDF)
Figure S2 NB1691 and SK-N-AS cells were treated with
GD2-miR34a-NPs in vitro and cell counts were per-
formed. Relative to GD2-miRneg-NP-treated controls, the
presence of miR-34a led to a significant reduction in cell numbers
in both cell lines 48 and 72 hrs post-treatment (***p,0.001,
n=3).
(TIF)
Figure S3 HEK293 cell sensitivity to miR-34a treat-
ment. (a) Reverse transfection of HEK293 cells with synthetic
premiR-34a resulted in ,600 fold increase in miR-34a expression
levels, relative to miRneg-treated controls, as determined by
qPCR (***p,0.001; n=3). (b) HEK293 cells showed a significant
reduction in viable cell numbers in the presence of premiR-34a,
quantified by acid phosphatase assay (***p,0.001, n=3).
(TIF)
Figure S4 IMR-90 cell sensitivity to miR-34a treatment.
(a) Human fibroblast (IMR-90) cells which were treated with
premiR-34a showed a significant reduction in viable cell number
over a 96 hour period using an acid phosphatase assay
(***p,0.001, n=3). (b) A corresponding induction of caspase 3/
7 activity was noted 72 and 96 hrs post-treatment with premiR-
34a (**p,0.01, n=3).
(TIF)
Figure S5 Tumor size evaluation prior to in vivo
nanoparticle treatment. (a) Ultra-sonography and (b) biolu-
minescence analysis on day 13 post tumor induction (prior to
nanoparticle injection) indicated equivalency of tumor sizes in
GD2-miR34a-NP versus GD2-miRneg-NP treated cohorts.
(TIF)
Figure S6 Tumor volumes (day 25) and post-mortem
tumor weights. Tumor volumes were measured by ultrasound
pre- and post-treatment in NB1691
luc and SK-N-AS
luc miR-34a
treated and control cohorts. Treatment of both neuroblastoma
subtypes with GD2-miR34a-NPs resulted in a significant reduction
in tumor volume (a-b **p,0.01, n=8). Additionally, post-mortem
tumor weights were shown to be significantly decreased in GD2-
miR34a-NP-treated groups relative to their GD2-miRneg-NP
treated counterparts (c-d **p,0.01, n=8).
(TIF)
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GD2-miR34a-NP treatment. Quantitative PCR analysis of
miR-34a expression levels was carried out on liver, kidney and
lung tissue from GD2-miR34a-NP and control treated cohorts in
both SK-N-AS
luc (a-c) and NB1691
luc (d-f) MiR-34a levels were
not significantly increased in healthy tissues subsequent to
treatment with GD2-miR34a-NP, validating the tumor-specific
targeting of the GD2-nanaoparticles used in this study.
(TIF)
Figure S8 Blood chemistry analysis subsequent to GD2-
miR34a-NP treatment. Complete blood chemistries were
analysed in response to systemic delivery of GD2-miRneg-NP
and GD2-miR34a-NPs, including serum levels of blood urea
nitrogen (BUN, a), alanine aminotransferase (ALT, b), albumin (c),
alkaline phosphatase (ALT, d), amylase (e), calcium (f), creatine (g),
globulin (h), glucose (i), phosphorus (j), total bilirubin (k) and total
protein (l n-=8, mean+sem). Grey-shaded areas indicate guideline
ranges as reported by the animal research centre at St. Jude
Children’s Research Hospital. Notably, with the exception of
creatine levels in NB1691
luc and SK-N-AS
luc and globulin and
total protein levels in SK-N-AS
luc treated animals, all values fall
within normal ranges; suggesting that administration of the
nanoparticles does not appear to adversely affect liver or kidney
function within mice in the context of this study.
(TIF)
Figure S9 Association of low levels of TIMP2 mRNA with
poor patient overall and event free survival.
(TIF)
Figure S10 (A) The sequence of both wild type and
mutant 39 UTR for TIMP2 (B) TIMP2 39UTR was PCR
amplified from genomic DNA using flanking primers.
(PDF)
Table S1 Clinical and biological characteristics of
neuroblastoma tumor cohort.
(XLSX)
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